Specifically, high baseline levels of sPD-L1 were found to be negatively associated with clinical benefit in malignant melanoma and non-small cell lung cancer (NSCLC) patients treated with anti-CTLA-4 or anti-PD-1 mAbs, respectively [20,29]. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.